Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBT Margin: 2019-2025

Historic EBT Margin for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -3,350.90%.

  • Kymera Therapeutics' EBT Margin fell 142137.00% to -3,350.90% in Q3 2025 from the same period last year, while for Sep 2025 it was 139,746.22%, marking a year-over-year increase of 13997512.00%. This contributed to the annual value of -8,447.87% for FY2024, which is 823700.00% down from last year.
  • Kymera Therapeutics' EBT Margin amounted to -3,350.90% in Q3 2025, which was down 354.20% from -737.76% recorded in Q2 2025.
  • Kymera Therapeutics' EBT Margin's 5-year high stood at 220.94% during Q4 2024, with a 5-year trough of -3,350.90% in Q3 2025.
  • For the 3-year period, Kymera Therapeutics' EBT Margin averaged around -808.73%, with its median value being -479.41% (2023).
  • As far as peak fluctuations go, Kymera Therapeutics' EBT Margin spiked by 29,870bps in 2021, and later tumbled by 142,137bps in 2025.
  • Kymera Therapeutics' EBT Margin (Quarterly) stood at -222.88% in 2021, then crashed by 1,684bps to -239.72% in 2022, then skyrocketed by 19,929bps to -40.44% in 2023, then soared by 26,137bps to 220.94% in 2024, then crashed by 142,137bps to -3,350.90% in 2025.
  • Its EBT Margin was -3,350.90% in Q3 2025, compared to -737.76% in Q2 2025 and -337.10% in Q1 2025.